Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Longduoduo delays annual report filing after book-close calculation setback

Longduoduo delays annual report filing after book-close calculation setback

BitgetBitget2026/09/28 18:46
  • Longduoduo filed a late notice for its annual report on Form 10-K for the year ended June 30, 2026.
  • The filing was delayed by slower-than-expected calculations needed to close the books, triggering a Rule 12b-25 extension request.
  • The company expects to file the Form 10-K within 15 calendar days of the original due date.
  • It did not anticipate a significant change in results of operations versus the prior-year period.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longduoduo Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-103959), on September 28, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Uncertainty clouds the US stock IPO market as smart ring manufacturer Oura (OURA.US) joins the ranks of delayed listings

Oura (OURA.US) has become the latest company to postpone its initial public offering (IPO) in the United States due to market uncertainty.

智通财经•2026/09/29 11:36

AstraZeneca (AZN.US) invests in Summit (SMMT.US), gaining positive outlooks from JPMorgan and Citi: Cancer drug strategy awaits validation

Analysts from JPMorgan and Citi have welcomed the deal between AstraZeneca and Summit Therapeutics, stating that it aligns with AstraZeneca's cancer strategy.

智通财经•2026/09/29 11:06